Circle Pharma Announces Presentation at the American Association for Cancer Research 2022 Annual Meeting

Circle Pharma Announces Presentation at the American Association for Cancer Research 2022 Annual Meeting




Circle Pharma Announces Presentation at the American Association for Cancer Research 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Circle Pharma, a pre-clinical stage company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, will present a poster at the American Association for Cancer Research (AACR) Annual Meeting being held April 8-13, in New Orleans, Louisiana.

The Company’s presentation will provide details of its progress towards structure-guided macrocycles that inhibit the protein-protein interaction between the cyclin A:CDK2 complex and key substrates that are phosphorylated by this complex. Inhibition of Cyclin A substrate binding has been postulated to be synthetic lethal in Rb mutated cancers. The data presented include evidence that macrocycle inhibitors of cyclin A induce G2/M arrest and apoptosis in small cell lung cancer (SCLC) cell lines and have anti-tumor efficacy in SCLC xenograft animal models. Circle plans to advance its cyclin A inhibitor program to the clinic for testing in a range of cancer types, including SCLC where Rb mutations are highly prevalent.

The presentation will be made as part of the Mechanisms of Drug Action / Experimental and Molecular Therapeutics session at the AACR meeting, Abstract No. 5379.

About Circle Pharma, Inc.

Circle is a pre-clinical stage company deploying a platform that combines structure-based rational drug design and advanced synthetic chemistry to develop first-in-class macrocycle therapeutics for challenging targets to address unmet clinical needs. Circle’s technology facilitates the design and synthesis of intrinsically cell-permeable macrocycles that can address both intra- and extra-cellular therapeutic targets, and can be delivered by multiple routes, including oral administration. Circle’s macrocycle drug discovery & development platform is applicable across a wide range of serious diseases; the company is initially focusing its development efforts on intracellular protein-protein interactions that are key drivers in cancer. Its lead programs target cyclin proteins, including cyclins A and E, which are part of the regulatory machinery that controls progression of cells through the cell cycle. Inhibition of cyclin A has been reported to be synthetic lethal to cancer cells that carry mutations causing dysregulation of the Rb pathway – such mutations are frequently found in small cell lung cancer. Cyclin E upregulation is found in many tumor types including uterine and ovarian cancer and is often associated with resistance to widely used cancer therapies, including trastuzumab and cdk4/6 inhibitors.

Contacts

More information: www.circlepharma.com
Contact: info@circlepharma.com
Eleonor Lim: 650.825.4099